ProKidney Corp. Class A Ordinary Shares (PROK)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 231
- Market Cap
- $337M
About ProKidney Corp. Class A Ordinary Shares
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
SentiSense also tracks daily options readings for ProKidney Corp. Class A Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
ProKidney Corp. Class A Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.